

Dynamic Generation of G-quadruplex DNA Ligands by Target-Guided Combinatorial Chemistry on a Magnetic Nano-platform

Snehasish Jana, Deepanjan Panda, Puja Saha, Dan Pantos, and Jyotirmayee Dash

J. Med. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jmedchem.8b01459 • Publication Date (Web): 11 Dec 2018

Downloaded from <http://pubs.acs.org> on December 13, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Dynamic Generation of G-quadruplex DNA Ligands by Target-Guided Combinatorial Chemistry on a Magnetic Nano-platform

Snehasish Jana^{†[a]}, Deepanjan Panda^{†[a]}, Puja Saha^[a], G. Dan Pantoş^[b] and Jyotirmayee

Dash^{[a]}*

^[a] School of Chemical Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata-700032, India, E-mail: ocjd@iacs.res.in; Fax:+91-33-2473-2805; Tel: +91-33-2473-4971, ext 1405.

^[b] Department of Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY (UK)

ABSTRACT: Dynamic combinatorial chemistry (DCC) has emerged as a promising strategy for template-driven selection of high-affinity ligands for biological targets from equilibrating combinatorial libraries. However, only a few examples using disulphide exchange based DCC are reported for nucleic acid targets. Herein, we have demonstrated that gold-coated magnetic nanoparticle conjugated DNA targets can be used as templates for dynamic selection of ligands from an imine-based combinatorial library. The implementation of dynamic combinatorial chemistry using DNA-nanotemplates enables efficient identification of the lead compounds, from the DCL via magnetic decantation. It further allows quick separation of DNA-nanotemplates for reuse in DCC reactions. The identified lead compound exhibits significant

1
2
3 quadruplex-vs.-duplex DNA selectivity and suppresses promoter activity of *c-MYC* gene that
4 contains G-quadruplex DNA forming sequence in the upstream promoter region. Further cellular
5 experiments indicated that the lead compound is able to permeate into cell nuclei and trigger a
6 DNA-damage response in cancer cells.
7
8
9
10
11
12

13 INTRODUCTION

14
15
16 Target-guided synthetic (TGS) approaches have been considered as powerful strategies to
17 discover novel and selective small molecules for biological targets by bridging the gap between
18 chemical synthesis and screening assays.¹⁻⁸ Dynamic Combinatorial Chemistry (DCC), a
19 thermodynamically controlled target-guided synthetic approach has been employed for the
20 identification of selective ligands in a cost- and time-effective manner.¹⁻⁸ In DCC, simple
21 molecular building blocks assemble through reversible bond formation to generate a dynamic
22 combinatorial library (DCL) consisting of a mixture of continuously inter-convertible products.
23 In the presence of a template, the equilibrium of the system shifts towards the formation of those
24 DCL components that strongly bind to the template at the expense of weak binders. Thus, this
25 concept provides an unique platform for the in-situ generation of high-affinity binders, offering
26 new opportunities for bio-medicinal applications.⁹⁻¹⁴ DCC has also been effectively used for the
27 development of hosts for small molecules,¹⁰ interlocked molecules,^{11,12} and catalysts¹³ as well as
28 for the functionalization of liposomes, nanoparticles etc.¹⁴
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 However, only a limited number of studies have been reported for the development of small
47 molecule probes for proteins¹⁵⁻¹⁸ and nucleic acids.¹⁹⁻²⁷ The Miller group first reported the
48 application of DCC to generate ligands for double stranded DNA.¹⁹ The Balasubramanian group
49 used disulphide chemistry based DCC to identify selective binders for G-quadruplex targets.²²⁻²⁴
50 DCC has also been used for developing RNA binding ligands.²⁵⁻²⁷ To improve the identification
51
52
53
54
55
56
57
58
59
60

1
2
3 of small molecule ligand(s) from DCL, Miller and co-workers have devised resin bound DCC²⁸
4 and the Otto group has recently reported nanoparticle functionalized building blocks for DCC.²⁹⁻
5
6
7
8 ³⁰ Most of these studies employ the disulphide-exchange chemistry that has several advantages
9
10 like water compatibility and very fast thiol-exchange property at mild pH.³¹ However, the
11
12 resulting disulphide leads may lose their druggability due to their instability in cellular
13
14 environment.³² On the other hand, imine-exchange based DCC using aldehyde and amine
15
16 building blocks produces the imine-leads, which could be reduced to stable amine products^{15, 20}
17
18 for further biophysical and cellular studies.


19
20
21 In this study, we have employed gold-coated magnetic nanoparticle-conjugated G-quadruplex
22
23 DNA (G₄-DNA nano-template), as templates³³ for dynamic selection of G-quadruplex DNA
24
25 ligands from aldehyde and amine building blocks. We envisaged that the G₄-DNA nano-template
26
27 would accelerate the identification of high-affinity ligands by providing multiple templates on
28
29 the surface of gold coated magnetic nanoparticles, simplify the separation of ligands and enable
30
31 the isolation of DNA nano-template by magnetic decantation. The selective ligands have the
32
33 potential to exhibit anticancer activities by stabilizing the quadruplex nucleic acids.³⁴⁻⁴³
34
35
36
37
38
39

40 RESULTS AND DISCUSSION

41
42 **Design and synthesis of aldehyde and amine building blocks.** In our design, we have used a
43
44 carbazole aldehyde **1** and a series of amines **2a-j** (**Scheme 1**) to develop specific ligand for G-
45
46 quadruplex DNA. Carbazole aldehyde **1** was selected as a building block as it can interact with
47
48 the terminal quartets of G₄-DNA via π - π aromatic stacking interactions.^{33,44} The aldehyde **1** was
49
50 prepared from commercially available carbazole via mono-iodination, N-alkylation followed by
51
52 Vilsmeier-Haack formylation⁴⁵ and Suzuki coupling⁴⁶ in good overall yield (**Figure S1**,
53
54
55
56
57
58
59
60


Supporting Information, S.I.). The 10-membered amine library **2a-j** includes aromatic and aliphatic amines that could be involved in electrostatic and hydrogen bonding interactions with DNA structures. The amines possess comparable reactivity to avoid biasness in the competition.

Scheme 1. (a) Aldehyde (1) and amine (2a-j) building blocks for DCC (b,c) 10 member dynamic combinatorial imine (3a-j) library and the corresponding reduced imines (4a-j).



1
2
3
4
5
6 The aldehyde **1** and amines **2a-j** building blocks would reversibly react to form imines **3a-j**
7
8 under near physiological conditions. Subsequently, the imine(s) formed could be irreversibly
9
10 reduced to stable amines **4a-j** by NaBH₃CN providing an equilibrated mixture for analysis. The
11
12 reversibility of the reaction is a key factor for developing a Dynamic Combinatorial Library
13
14 (DCL). To establish the reversibility of the system, aldehyde **1** was continuously stirred with an
15
16 excess of amine **2e** in MOPS buffer (20 mM, pH 6.5) containing 100 mM KCl for 12 h. The
17
18 MOPS buffer was used to maintain a slightly acidic medium, which is optimal for imine
19
20 exchange reaction and the buffer system containing 100 mM KCl is suitable to maintain the four
21
22 stranded conformation of the G₄-DNA in near physiological pH.⁴⁷ An aliquot of the resulting
23
24 mixture was analyzed by ESI mass spectrometry confirming the formation of the corresponding
25
26 imine **3e** (Figure S2). The amine **2d** was then added in excess to the reaction mixture and the
27
28 reaction was continued for another 12 h. The ESI mass analysis of the resultant mixture showed
29
30 the presence of both the imines **3d** and **3e** (Figure S3). The formation of both imines indicates
31
32 that imine **3e** was converted to imine **3d** via reversible exchange and thus, these building blocks
33
34 are suitable for DCC reaction (Scheme 2).
35
36
37
38
39
40

41 **Scheme 2. Reversible exchange between imines 3e and 3d in MOPS buffer (20 mM, pH 6.5)**
42 **containing 100 mM KCl.**



1
2
3 **DNA templated imine exchange DCC.** The 10-membered amine library (**2a-2j**) was then
4 exposed with the aldehyde **1** to form a DCL and left to equilibrate for 18 h at 25 °C in MOPS
5 buffer (20 mM, pH 6.5) with 100 mM KCl. Five-fold excess of each amine was used for the
6 complete consumption of aldehyde **1**. Then, NaBH₃CN was added to the reaction mixture and
7 incubated for 6 h at the same temperature for switching the system towards irreversibility. The
8 HPLC chromatogram of this reaction mixture provided overlapping peaks and ESI mass analysis
9 of the HPLC fractions revealed the formation of all the corresponding amines **4a-j** without any
10 considerable selection (**Figure 3a**).
11
12
13
14
15
16
17
18
19
20
21

22 The reaction was then performed in the presence of a G-quadruplex nano-template (G₄-
23 AuMNp) and a duplex DNA nano-template (*ds*DNA-AuMNp) under similar reaction conditions.
24 We have taken a thiolated G-quadruplex forming sequence present in the promoter region of *c*-
25 *MYC* oncogene.^{48,49} The G₄-AuMNp was prepared by immobilizing thiolated G₄-DNA on gold-
26 coated magnetic nanoparticles. Similarly, a control self-complementary duplex DNA
27 nanotemplate, (*ds*DNA-AuMNp) was prepared by attaching a thiolated *ds*DNA sequence on
28 gold-coated magnetic nanoparticles (**Figure 1a**). The G₄-AuMNp and *ds*DNA-AuMNp templates
29 were characterized by using TEM, UV-Vis and Circular Dichroism spectroscopy. These studies
30 revealed that DNA functionalized nanoparticles were 10-15 nm in diameter (**Figure 1b & 1d**)
31 and they displayed absorption peaks near 260 nm along with the typical SPR peak of Au at 535
32 nm (**Figure 1e-f**). The G₄-AuMNp exhibited a positive peak at 260 nm and negative peak at 240
33 nm in CD spectroscopy indicating that G₄-AuMNp maintains the parallel conformation of G-
34 quadruplex structure (**Figure 1c**). The CD spectrum of *ds*DNA-AuMNp also showed a positive
35 signal at 275 nm and a negative signal at ~250 nm corresponding to the duplex DNA
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 conformation (**Figure 1c**). Moreover, these DNA coated magnetic nanoparticles could be easily
4 dispersed in aqueous media and could also be isolated by using magnetic separation.
5
6

7
8 In order to perform DCC reactions with DNA nano-templates, the aldehyde and amine
9 building blocks were incubated in the presence of G₄-AuMNp or dsDNA-AuMNp for 18 h in
10 MOPS buffer (20 mM, 100 mM KCl), pH 6.5 at RT. To this mixture of interconvertible imines,
11 NaBH₃CN was added and the mixture was stirred for 6 h for the complete reduction of imines to
12 the corresponding amines; thus, the system became irreversible (**Figure 2, Figure S4**).
13
14 Subsequently, amine bound DNA nano-templates were separated by magnetic decantation and
15 the unbound amines remained in the supernatant. The isolated DNA-AuMNps were washed three
16 times with MOPS buffer and the resulting suspension was heated at 65 °C to release the template
17 bound amine products. Then DNA-AuMNps were instantly separated by an external magnet and
18 the supernatant was characterized by HPLC and ESI-MS analysis to identify the lead amine
19 products.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 1. (a) Schematic representation of the preparation of G₄-AuMNP (Seq.: 5'-[ThiC6]-TG₄AG₃TG₄AG₃TG₄A₂G₂-3') and dsDNA-AuMNP (Seq.: 5'-[ThiC6]-CA₅T₅GCA₅T₅G-3'). (b) TEM image of dsDNA-AuMNP. (c) CD spectra of G₄-AuMNP and dsDNA-AuMNP in 20 mM MOPS buffer (pH 6.5, 100 mM KCl). (d) TEM image of G₄-AuMNP. (e-f) Absorption spectra of dsDNA-AuMNP and G₄-AuMNP in 20 mM MOPS buffer (pH 6.5, 100 mM KCl).

1
2
3 Significant changes in the composition of DCL were observed in the presence of G₄-DNA and
4 *ds*DNA nano-templates (G₄-AuMNp and *ds*DNA-AuMNp) (**Figure 3** and **Figure S5**). The
5 HPLC retention times and the mass analysis of the products revealed that amine **4e** (reduced
6 product of imine **3e**, derived from **1** and **2e**) was exclusively obtained in the presence of G-
7 quadruplex nano-template out of 10 possible amine products **4** (**Figure 3f**). In the presence of
8 *ds*DNA nano-template, five amine products **4g**, **4h**, **4i**, **4f** and **4b** (reduced products of imines
9 **3g**, **3h**, **3i**, **3f** and **3b**, respectively) were identified (**Figure 3b**). These results indicate that amine
10 **4e** is a selective lead for the G-quadruplex target. Furthermore, **4e** was exclusively obtained by
11 giving a shorter reaction time (i.e. 30 min to 4 h) for the reduction step (**Figure S6**, **S.I.**).
12
13
14
15
16
17
18
19
20
21
22
23

24 Next, we performed the DCC using the same aldehyde and amine library and after 18
25 h equilibration period, the imine-bound G₄-AuMNps were separated and reduced by
26 NaBH₃CN. The HPLC and ESI-MS results revealed that ligand **4e** was exclusively obtained,
27 indicating G₄-AuMNp selects the best binder (i.e. **3e**) from the imine DCL due to higher affinity
28 of imine **3e** and then **3e** was reduced to stable amine (**4e**) upon addition of NaBH₃CN (**Figure**
29 **S7**, **S.I.**). In comparison, by using solution phase DCC with free quadruplex DNA, we observed
30 a complex mixture of compounds in the HPLC chromatogram (**Figure S8**), making lead
31 identification difficult.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



31 **Figure 2. Schematic representation of imine exchange based dynamic combinatorial**
32 **chemistry using G₄-AuMNp template.**
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. HPLC analysis of the DCL (a) without any external template and using (b) *dsDNA*-AuMNP and (c-f) *G*₄-AuMNP after 4 h, 6 h, 12 h, 18 h respectively. HPLC chromatogram of pure compound (g) 4e (h) 4g and (i) 4h.

1
2
3 Next, we carried out a time-dependent imine exchange DCC reaction of the same library in the
4 presence of G₄-AuMNP to optimize the time required for the amplification of **4e**. For this
5 purpose, we collected aliquots of the reaction mixture after 4 h, 6 h, 12 h and 18 h and then
6 reduced using NaBH₃CN. Following the similar procedure, the lead compounds were isolated
7 from each reaction mixture using magnetic separation and then analyzed by HPLC and ESI-MS
8 (**Figure 3c-e**). The time-dependent HPLC analysis revealed that ligands **4e**, **4g** and **4h** were
9 formed in a ratio of ~ 25:12:10 respectively after 4 h, indicating the corresponding imines **3e**, **3g**
10 and **3h** were in equilibrium in the presence of G₄-DNA nanotemplates. As the time progressed,
11 continuous elevation in the LC response signal of **4e** was noticed and the LC response signals of
12 **4g** and **4h** were gradually decreased at 6 and 12 h time period. Finally, after 18 h, ligand **4e** was
13 exclusively formed and by giving longer equilibration time up to 48 h, ligand **4e** was obtained as
14 the sole product (**Figure S9, SI**), illustrating that the system has reached thermodynamic
15 equilibrium by 18 h. For further validation, the DCL was pre-equilibrated for 24 h and then
16 incubated with G₄-AuMNP for 18 h; this DCL also produced **4e** exclusively. These observations
17 indicate that among the possible amine products, **4e** exhibits higher binding affinity and
18 selectivity for the G₄-DNA over dsDNA (**Figure 4**) as other lead products **4g** and **4h** were also
19 formed in the presence of dsDNA nanotemplate. Furthermore, when we mixed the G₄-AuMNP
20 with all the synthesized amines (pure **4a-j**), LC response of **4e** and **4g** was observed (**Figure S10,**
21 **S.I.**), indicating that the amplification of **4e** in DCC is not mediated by mere affinity capture by
22 DNA templates. Here, the imine DCL evolves and self-corrects in the presence of G₄-
23 nanotemplate to amplify its best binder at the expense of other weak imine products. It is also
24 interesting to mention that the quadruplex nano-template could be recovered and reused for five
25 DCC reaction cycles (**Figure S11, S12, S.I.**).




Figure 4. Comparison of relative composition of the DCL in presence of G₄-AuMNP with time interval of 4 h, 6 h, 12 h and 18h.

Validation of lead compounds by biophysical analysis. To further validate these findings, all possible amine products (**4a-4j**) were synthesized (**Figure S13, S.I.**) and their ability to stabilize the G-quadruplex DNA was investigated by Förster Resonance Energy Transfer (FRET) based DNA melting assays⁵⁰ using FAM and TAMRA labelled G-quadruplex and double stranded DNA sequences at 1 μ M ligand concentration (**Table 1, Figure S14, S.I.**). Interestingly, the lead compound **4e** showed high stabilization potential for G₄-DNA ($\Delta T_m = 23.4$ °C) over dsDNA ($\Delta T_m = 0.6$ °C). The other two lead two compounds **4g** and **4h** showed ΔT_m values of 13.6 °C and 11.8 °C for G₄-DNA and ΔT_m values of 9.5 °C and 8.5 °C for dsDNA, respectively. Ligands **4a** with aromatic hydroxyl group, **4b** with aromatic nitro group, bromo-substituted amine product **4c** and **4d** with tertiary propyl amine side chain, **4f** with thiazole side chain and **4j** with neutral cyclopropane side chain exhibited weak stabilization potentials with low ΔT_m values for G₄ and duplex DNA. The cationic tertiary amine side chain containing compound **4i** showed

1
2
3 moderate stabilization potential for both dsDNA ($\Delta T_m = 7.2$ °C) and G₄-DNA ($\Delta T_m = 5.3$ °C). In
4
5 addition, to assess the selectivity of ligand **4e** for G₄-DNA, we performed competitive FRET
6
7 experiments with 0.2 μ M of labelled G₄-DNA (*c-MYC*) and 1 μ M **4e** with increasing
8
9 concentrations of non-labelled calf-thymus duplex DNA (ctDNA) competitor. These results
10
11 showed that the ΔT_m value of *c-MYC* G₄-DNA with 1 μ M **4e** was not altered in the presence of
12
13 excess ctDNA (1-200 eq of *c-MYC* G₄-DNA) (**Figure S15, S.I.**), indicating ligand's selectivity
14
15 for quadruplex DNA over duplex DNA. Circular Dichroism spectroscopy further revealed that
16
17 the characteristic CD signature for the native parallel topology of *c-MYC* G₄-DNA (a positive
18
19 peak at 260 nm and a negative peak at 240 nm) was retained in the presence of ligand **4e**, even at
20
21 10 eq concentrations (**Figure S16, S.I.**). These suggest that **4e** binds and stabilizes the
22
23 quadruplex DNA without perturbing its parallel conformation.
24
25
26
27

28 **Table 1. ΔT_m values of ligands at 1 μ M concentration for *c-MYC* G₄ and dsDNA in 60 mM**
29 **potassium cacodylate buffer, pH 7.4.**
30
31
32
33

Ligands	ΔT_m (°C)	
	<i>c-MYC</i> G ₄	dsDNA
4a	0.7	1.9
4b	3.4	2.4
4c	3.3	0.44
4d	5.0	3.79
4e	23.4	0.58
4f	3.2	1.15
4g	13.6	9.5
4h	11.8	8.5
4i	5.3	7.2
4j	3.5	1.1

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 T_m of *c-MYC* G₄-DNA is 70.1°C and dsDNA is 65°C in the
52 absence of ligands. DNA concentration: 200 nM.
53
54
55
56
57
58
59
60

1
2
3 The binding affinities of the lead compounds (**4e**, **4g** and **4h**) for G₄-DNA and dsDNA were
4 determined using fluorescence spectroscopic titrations. As shown in **Figure 5**, ligand **4e**
5 exhibited emission maximum at 400 nm (λ_{max}^{em}) when excited at 300 nm (λ_{ex}). Upon incremental
6 addition of G₄-DNA, the emission intensity of **4e** at 400 nm was enhanced by 4.4 fold and a
7 large red-shift of 50 nm of the emission maximum was observed eventually leading to a new
8 emission maximum at around 450 nm (**Figure 5a**, **Figure S17**, **SI**). The observed red shift arises
9 from the strong binding interactions of **4e** with DNA G-quadruplex, which restricts the rotation
10 of the 4-methoxy phenyl ring relative to the carbazole moiety in the excited state. With dsDNA,
11 no significant change in the fluorescence intensity of **4e** was observed indicating its excellent
12 selectivity for G-quadruplex DNA (**Figure 5b**). The titration of compound **4g** ($\lambda_{max}^{em} = 397$ nm,
13 $\lambda_{ex} = 300$ nm) with G₄-DNA and dsDNA showed that the fluorescence intensity was decreased
14 by 2.3-fold and 1.5 fold respectively (**Figure 5c-d**). The fluorescence intensity of **4h** ($\lambda_{max}^{em} = 396$
15 nm, $\lambda_{ex} = 300$ nm) was also decreased by 1.5 fold with both G₄-DNA and dsDNA (**Figure 5e-f**).
16
17 Ligand **4e** displayed an apparent K_d value of 1.08 ± 0.2 μ M for G₄-DNA whereas **4g** and **4h**
18 showed higher K_d values for G₄-DNA (**Table 2**). These results are consistent with the results
19 obtained using DCC, suggesting that ligand **4e**, exclusively formed in the presence of G₄-
20 AuMNP shows selective binding affinity to G₄-DNA compared to other lead compounds **4g** and
21 **4h** formed by giving short equilibration time (4-12 h).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Fluorescence emission spectra of lead compounds with G₄-DNA and dsDNA. Conditions: [Ligand] = 0.25 μ M; 100 mM Tris.KCl buffer, pH 7.4, Excitation wavelength 300 nm.

Table 2. Apparent dissociation constants (K_d) obtained from fluorimetric titration and DC₅₀ values obtained from FID assay for the lead compounds for G₄-DNA and dsDNA in 100 mM Tris.KCl buffer (pH 7.4).

Ligands	K_d (μ M)		DC ₅₀ (μ M)	
	G ₄ -DNA	dsDNA	G ₄ -DNA	dsDNA
4e	1.08 \pm 0.2	N.d.	2.25	> 30
4g	5.72 \pm 0.1	6.63 \pm 0.3	8.01	> 30
4h	7.17 \pm 0.3	7.03 \pm 0.2	> 25.0	> 30

The binding selectivity of the lead compounds for G-quadruplex DNA over duplex DNA was further corroborated by using Fluorescence intercalator displacement assay⁵¹ (FID, **Figure S18**). The FID assay was carried out using Thiazole orange (TO) as the fluorescent intercalator. For each ligand, FID experiments were performed with both G₄-DNA and dsDNA and the binding

affinities of ligands were evaluated in terms of DC_{50} values. In agreement with Fluorescence binding titrations, ligand **4e** exhibited a significantly higher ability to displace 50% TO from G_4 -DNA ($DC_{50} = 2.25 \mu\text{M}$) compared to *ds*DNA ($DC_{50} > 30 \mu\text{M}$) (**Figure S18**). The DC_{50} value of **4g** was determined to be $8.0 \mu\text{M}$ for the G_4 -DNA and $> 30 \mu\text{M}$ for *ds*DNA. In comparison, the 50 % threshold limit was not acquired by **4h** for the G_4 -DNA and *ds*DNA even at a concentration of $25 \mu\text{M}$ ($DC_{50} > 25 \mu\text{M}$) (**Table 2**). The FRET melting assay, fluorescence binding titrations and FID studies establish a direct correlation between DNA-mediated amplification of selective leads and their binding affinities for the DNA targets.

Biological activity of ligand 4e. XTT assay was carried out to evaluate the cytotoxicity of these compounds against human carcinoma cell lines HeLa and A549 as well as in normal human kidney epithelial cell line (NKE). Compound **4e** and **4g** showed significant cytotoxicity towards cancer cell lines (IC_{50} values of 2-6 μM) whereas compound **4h** exhibited weak cytotoxicity with low IC_{50} values (**Table 3**). Interestingly, these three lead compounds displayed negligible cytotoxicity for the human normal cell line.

Table 3. Effect of compounds on the cell viability after 24 h exposure in HeLa, A549 and NKE cell line.

Compounds	IC_{50} (μM)		
	HeLa	A549	NKE
4e	2.5	6.4	> 50
4g	2.0	4.3	> 50
4h	11.5	> 25	> 50

1
2
3 We further carried out dual luciferase reporter assay⁵² to study their ability to inhibit oncogenic
4 transcription by interacting with the G-quadruplex (**Figure 6a**). We used plasmid constructs
5 containing wild-type *c-MYC* G-rich promoter sequence⁵³ (WT *c-MYC* Luc) as well as mutant (G-
6 to-A) *c-MYC* promoter sequence (Mut *c-MYC* Luc) upstream of the firefly coding gene (**Figure**
7 **6b**). A control plasmid, pRL-TK (Renilla luciferase, linked to the non G-rich thymidine kinase
8 promoter) was co-transfected with *MYC* Luc constructs as a loading control. HeLa cells were
9 treated with each ligand at concentrations of 1 and 1.5 μ M for 36 h after co-transfection. Ligand
10 **4e** reduced the *c-MYC* promoter-linked expression by 31 % and 45 % at 1 and 1.5 μ M
11 concentrations (**Figure 6c**).
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. (a) Schematic representation of ligand-mediated downregulation of *c-MYC* gene.

(b) Firefly luciferase constructs containing either the WT or mutant *c-MYC* promoter G-

1
2
3 rich sequence. (c) Histogram demonstrating effect of compounds on the *c-MYC* promoter
4 activity, determined by dual luciferase reporter assay. (d) Western Blot bands of *c-MYC*
5 and GAPDH proteins after 24 h treatment with ligand **4e** at three different concentrations
6 (1.0 μM , 1.5 μM and 2.0 μM). (e) Bar diagram showing dose-dependent downregulation of
7 *c-MYC* protein by **4e**. (f) Confocal imaging of cells treated with 0.5 μM **4e**. Nucleus staining
8 dye is NucRed647 and scale bar is 20 μm . (g) Ligand **4e** induced DNA damage response in
9 HeLa cells as indicated by the increase of Alexa Fluor 647-tagged anti- γ -H2AX stained cell
10 population in Flow cytometry.
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 However, the transcriptional activity of mutant plasmid construct was not inhibited with
26 increasing concentrations of **4e**. Ligand **4g** exhibited less pronounced transcriptional inhibition
27 (14 % at 1.5 μM) whereas **4h** could not inhibit promoter activity in HeLa cells. The Western
28 Blot analysis confirmed that the major lead compound **4e** could inhibit the MYC expression in
29 HeLa cells in a dose-dependent manner (**Figure 6d-e**). Ligand **4e** repressed the MYC protein
30 expression by 27 % at 1.0 μM , 57 % at 1.5 μM and by 65 % at 2.0 μM concentrations without
31 affecting the expression of the house keeping gene, GAPDH. These results establish that **4e**
32 could downregulate *c-MYC* expression at both transcriptional and translational level by directly
33 targeting its promoter quadruplex.⁵⁴⁻⁵⁸ Further investigations revealed that the ligand **4e** localizes
34 into the cell as well as within the cell nuclei (**Figure 6f**). To investigate whether ligand **4e** could
35 induce DNA-damage response in cancer cells, flow cytometric assays were carried out with
36 Alexa Fluor 647-tagged anti- γ -H2AX. As shown in Figure 6g, a significant increase in the γ -
37 H2AX foci (a significant marker for DNA damage response) was observed after treatment with
38 **4e** for 24 h at 1 μM and 2 μM concentration. This indicates that ligand **4e** triggers DNA damage
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 response in cancer cells. Molecular docking studies further revealed that carbazole core of **4e**
4 stacks on the terminal G-quartet plane of G₄-DNA (PDB ID: 1XAV)⁵⁹ by π - π interaction and the
5 aromatic cationic side chain interacts with DNA phosphate backbone via electrostatic
6 interactions (**Figure S19a, S.I.**). Interestingly, imine **3e** shows more preferred stacking
7 interactions on G-quartet by mostly exhibiting similar binding mode with G₄-DNA (**Figure**
8 **S19b, S.I.**). Collectively, these observations gave an understandable explanation regarding the
9 selectivity of **4e** for G₄-DNA compared to other possible amine products.

19 **Conclusions**

20
21 In conclusion, we have demonstrated that a quadruplex nanotemplate can dynamically select
22 and amplify selective ligands for the quadruplex target from a pool of simple aldehyde and
23 amine building blocks. The present method allows efficient isolation and identification of
24 selective ligands for the quadruplex target as well as the recovery and reuse of DNA
25 nanotemplate. The lead ligand shows significant quadruplex-vs.-duplex selectivity and inhibits
26 gene expression by targeting its promoter quadruplex. The technique highlights quadruplex
27 selective ligands can be developed by using simple and straight-forward synthetic methods in
28 comparison to the previously reported ligands, often associated with synthetic complexity and
29 time-consuming purification and screening processes. In comparison to kinetically controlled
30 TGS approach, where the target selects and promotes irreversible bond formation between the
31 most potent reactive fragments to form the target selective products,³³ the thermodynamically
32 controlled DCC method uses reversible bond formation to generate all possible products and the
33 system evolves and self-corrects in the presence of a target to amplify the best binder at the
34 expense of other products. Together, these results illustrate that nanotemplate guided DCC
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 method could be potentially useful for the rapid generation of specific ligands for
4
5 biomacromolecular targets.
6
7
8
9

10 **EXPERIMENTAL SECTION**

11
12 **General information:** All solvents and reagents were purified by standard techniques or used as
13
14 supplied from commercial sources (Sigma-Aldrich Corporation® unless stated otherwise). All
15
16 reactions were generally carried out under inert atmosphere unless otherwise noted. TLC was
17
18 performed on Merck Kieselgel 60 F254 plates, and spots were visualized under UV light.
19
20 Products were purified by flash chromatography on silica gel (100-200 mesh, Merck). ¹H and ¹³C
21
22 NMR spectra were recorded on either Bruker ADVANCE 500 (500 MHz and 125 MHz), or
23
24 JEOL 400 (400 MHz and 100 MHz) instruments using deuterated solvents as detailed and at
25
26 ambient probe temperature (300 K). Chemical shifts are reported in parts per million (ppm) and
27
28 are referred to the residual solvent peak. The following notations are used: singlet (s); doublet
29
30 (d); triplet (t); quartet (q); multiplet (m); broad (br). Coupling constants are quoted in Hertz and
31
32 are denoted as *J*. Mass spectra were recorded on a Micromass® Q-ToF (ESI) spectrometer with
33
34 50% methanol solution. The purity of the synthesized aldehyde (**1**) and the final synthesized
35
36 compounds (**4a-j**) were confirmed to be higher than 95% by performing HPLC with a dual pump
37
38 Shimadzu LC-20 AD system equipped with an 5.0 μm ODS2 reverse phase column (4.6 × 250
39
40 mm) using 300 nm detection wavelength.
41
42
43
44
45

46
47 **Synthesis of AuMNP.** An aqueous solution of HAuCl₄ (5 mL, 2.0 mg/mL) was mixed into 20
48
49 mL of deionized water and boiled for 5 min. Then, 1 mL Fe₃O₄ nanoparticle solution
50
51 (synthesized by reported procedure)³³ was added into the reaction mixture followed by the
52
53 addition of sodium citrate (1 mL, 80 mmol). The color of the solution gradually changed from
54
55
56
57
58
59
60

1
2
3 brown to burgundy. The reaction mixture was refluxed under stirring for 5 min. After cooling,
4 the solution was sonicated for 10-15 min, and then gold-coated magnetic nanoparticles (AuMNp)
5 were collected using a magnet, washed 3 times and re-dispersed in pure water. Carbazole
6 aldehyde **1** was prepared from commercially available carbazole **S1** (Figure S1).
7
8
9
10
11
12
13

14 **Synthesis of DNA coated AuMNp (G₄-AuMNp and dsDNA-AuMNp).** All buffers and
15 solutions were degassed in order to avoid oxidative dimerization into disulfide dimers. Thiolated
16 DNA functionalized nanoparticles were synthesized by derivatizing 100 μ L of an aqueous
17 AuMNp nanoparticle solution with 100 μ L 5'-thiol capped DNA solution (oligonucleotide
18 concentration is 100 μ M in 20 mM MOPS buffer, pH 6.5, 100 mM KCl). Thiolated DNA
19 sequences were pre-annealed in 20 mM MOPS buffer (pH 6.5, 100 mM KCl) by heating at 95 $^{\circ}$ C
20 for 5 min followed by gradual cooling to room temperature at a controlled rate of 0.1 $^{\circ}$ C/min and
21 then kept at 4 $^{\circ}$ C for overnight.
22
23
24
25
26
27
28
29
30
31
32

33 After standing for 16 h with AuMNps, nanoparticles were separated using magnet and washed
34 with 20 mM MOPS buffer containing 100 mM KCl (pH 6.5). The volume of the nanoparticle
35 solution was made up to 100 μ L with the buffer. The HPLC purified thiol capped DNAs were
36 supplied by SIGMA Aldrich. The sequences of the DNAs are as follows;
37
38
39
40
41

42 G₄-DNA: 5'- [ThiC6] TG₄AG₃TG₄AG₃TG₄A₂G₂TG₄A -3'

43 dsDNA: 5'- [ThiC6] CA₅T₅GCA₅T₅G -3'

44
45
46
47
48
49 **Reversible exchange of imines.** In a 2 mL eppendorf, aldehyde **1** (20 μ L, 10 mM) was taken in
50 1 mL of MOPS buffer (20 mM, 100 mM KCl, pH 6.5) followed by the addition of amine **2e** (100
51 μ L 10 mM). The mixture was stirred at rt for 12 h. An aliquot of the resulting mixture was
52
53
54
55
56
57
58
59
60

1
2
3 analyzed by ESI mass spectrometry. Then the amine **2d** was added in excess (100 μ L 10 mM) to
4 the reaction mixture and the reaction was continued for another 12 h. The final reaction mixture
5 was also analyzed by ESI-MS.
6
7
8
9

10
11
12 **Procedure for G₄-AuMNp templated imine exchange.** In a 2 mL eppendorf, 40 μ L G₄-
13 AuMNp template (G₄-nanotemplate, \sim 20 μ M G₄-DNA) was taken in 500 μ L of MOPS buffer
14 (20 mM, 100 mM KCl, pH 6.5). Aldehyde **1** (5 μ M) was then added to the mixture, followed by
15 the addition of 25 μ M of each amine **2a-j**. The resulting mixture was stirred at rt for 18 h. Then,
16 NaBH₃CN (10 mg) was added to the DCL for the reduction of imines and the resulting mixture
17 was stirred for another 6 h. Subsequently, G₄-AuMNp template was separated from the reaction
18 mixture using a magnet and washed twice with MOPS buffer to remove the unbound amines.
19 Afterwards, the nanoparticles were dispersed in MOPS buffer (50 μ L) and the dispersion was
20 then heated for 5 min at 65 $^{\circ}$ C and the DNA-linked nanotemplate (G₄-AuMNps) was separated
21 instantly. The supernatant containing the amine lead compounds were identified by HPLC and
22 ESI-MS spectroscopy.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Templated imine exchange using dsDNA-AuMNp.** In a 2 mL eppendorf, 40 μ L dsDNA
41 nanotemplate (dsDNA-AuMNp) was added to 0.5 mL of 20 mM MOPS buffer (100 mM KCl,
42 pH 6.5). Aldehyde **1** (5 μ M) was then added to the mixture, followed by the addition of 25 μ M of
43 each amine **2a-j** building blocks. The resulting mixture was stirred at rt for 18 h. Then NaBH₃CN
44 (10 mg) was added to the DCL and the mixture stirred for another 6 h. After reduction, the lead
45 compounds for dsDNA was identified by following the above-mentioned separation technique.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

General procedure for the synthesis of reduced imines (4a-j). Carbazole aldehyde **1** (50 mg, 0.13 mmol) was dissolved in EtOH (4 mL) in the presence of molecular sieves. The desired amine **2 a-j** (0.13 mmol) was added separately and the mixture was stirred for 24 h at room temperature (Figure S11). The resulting reaction mixture comprising imines was dried under vacuum. Then MeOH (5 mL) and NaBH₃CN (20 mg) was added to the solid mass and stirred for another 6 h at room temperature. The mixture was concentrated under vacuum and was purified by flash column chromatography (from CH₂Cl₂ (100%) to CH₂Cl₂/MeOH (10:1) to CH₂Cl₂/MeOH/NH₄OH (10:1:0.5) to give the corresponding amines.

4-(((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)amino)phenol

(Amine 4a). Following the GP, the reaction of aldehyde **1** with amine **2a** (35.3 mg) afforded **4a** (61 mg, 65 %) as a black viscous liquid. ¹H NMR (400 MHz, CDCl₃): δ 8.51 (s, 1H), 8.19 (s, 1H), 8.04 (m, 1H), 7.91 (m, 2H), 7.89 (m, 2H), 7.62 (m, 2H), 7.45 (m, 3H), 6.93 (m, 2H), 4.31 (t, *J* = 6.2 Hz, 2H), 3.78 (s, 3H), 3.77 (s, 2H), 2.16 (t, *J* = 7.0 Hz, 2H), 2.13 (s, 6H), 1.92 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 157.9, 148.2, 144.5, 141.5, 135.2, 129.8, 129.3, 128.8, 128.6, 128.1, 127.7, 127.4, 127.1, 126.9, 124.1, 123.3, 123.2, 120.9, 109.7, 109.4, 56.5, 55.0, 47.1, 45.5, 41.1, 27.0; HRMS (ESI) Calcd for C₃₆H₄₅N₄O₂ [M+H]⁺ 480.2572, Found 480.2575.

N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)-4-nitroaniline

(Amine 4b). Following the GP, the reaction of aldehyde **1** with amine **2b** (25.3 mg) afforded **4b** (51 mg, 69 %) as a brown viscous liquid. ¹H NMR (400 MHz, CDCl₃): δ 8.60 (s, 1H), 8.28 (s, 1H), 8.12 (m, 1H), 7.99 (m, 2H), 7.69 (m, 2H), 7.63 (m, 2H), 7.52 (m, 3H), 7.02 (m, 2H), 4.40 (t, *J* = 6.2 Hz, 2H), 3.87 (s, 3H), 3.85 (s, 2H), 2.24 (t, *J* = 7.2 Hz, 2H), 2.22 (s, 6H), 2.01 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.4, 148.5, 144.5, 141.5, 135.2, 129.8, 129.5, 128.8,

1
2
3 128.6, 128.1, 127.7, 127.5, 127.4, 126.9, 124.1, 123.3, 123.2, 120.9, 109.7, 109.4, 56.4, 55.2,
4
5 48.2, 45.5, 41.1, 27.0; HRMS (ESI) Calcd for C₃₆H₄₅N₄O₂ [M+H]⁺ 509.2474, Found 509.2462.
6
7
8
9

10 **4-bromo-N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)-2-**
11 **methylaniline (Amine 4c).** Following the GP, the reaction of aldehyde **1** with amine **2c** (30 mg)
12 afforded **4c** (61 mg, 79 %) as a brown viscous liquid. ¹H NMR (400 MHz, CDCl₃): δ 8.54 (s,
13 1H), 8.29 (s, 1H), 7.64 (m, 1H), 7.62 (m, 1H), 7.51 (m, 1H), 7.47 (m, 2H), 7.32 (m, 3H), 7.02
14 (m, 2H), 6.91 (m, 1H), 4.42 (t, *J* = 6.1 Hz, 2H), 3.88 (s, 2H), 3.81 (s, 3H), 3.73 (s, 3H), 2.29 (t, *J*
15 = 6.8 Hz, 2H), 2.24 (s, 6H), 2.05 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ 158.1, 144.5, 141.5,
16 135.2, 129.7, 129.1, 128.8, 128.4, 128.1, 127.6, 127.4, 127.3, 127.0, 126.9, 124.1, 123.2, 120.8,
17 120.5, 111.8, 110.2, 109.7, 109.3, 56.5, 54.9, 51.7, 45.5, 41.3, 26.9, 19.7; HRMS (ESI) Calcd
18 for C₃₆H₄₅N₄O₂ [M+H]⁺ 556.1885, Found 556.1882.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **4-(3-(dimethylamino)prop-1-yn-1-yl)-N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-**
34 **carbazol-3-yl)methyl)aniline (Amine 4d).** Following the GP, the reaction of aldehyde **1** with
35 amine **2d** (35.3 mg) afforded **4d** (51 mg, 69 %) as a brown viscous liquid. ¹H NMR (400 MHz,
36 DMSO-d₆): δ 8.38 (s, 1H), 8.17 (s, 1H), 7.70 (m, 4H), 7.64 (m, 2H), 7.57 (m, 2H), 7.55 (m, 2H),
37 7.03 (m, 2H), 4.66 (s, 2H), 4.42 (t, *J* = 6.2 Hz, 2H), 3.80 (s, 3H), 3.16 (s, 3H), 2.32 (t, *J* = 7.0
38 Hz, 2H), 2.20 (s, 12H), 1.93 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆): δ 158.3, 150.3, 139.8,
39 139.6, 133.7, 133.2, 130.9, 127.8, 125.5, 124.4, 122.8, 122.1, 118.8, 117.7, 116.2, 115.6, 114.4,
40 113.3, 109.7, 109.0, 83.7, 82.3, 63.6, 62.7, 55.8, 55.3, 52.2, 48.7, 44.7, 26.1; HRMS (ESI) Calcd
41 for C₃₆H₄₅N₄O₂ [M+H]⁺ 545.3202, Found 545.3213.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **4-(3-(dimethylamino)propoxy)-N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-**
4 **carbazol-3-yl)methyl)aniline (Amine 4e).** Following the GP, the reaction of aldehyde **1** with
5
6 amine **2e** (25.3 mg) afforded **4e** (51 mg, 69 %) as a brown viscous liquid. ¹H NMR (500 MHz,
7
8 DMSO-d₆): δ 8.34 (s, 1H), 8.22 (s, 1H), 7.69-7.67 (m, 3H), 7.60 (d, *J* = 8.8 Hz, 1H), 7.53 (d, *J* =
9
10 8.2 Hz, 1H), 7.48 (d, *J* = 6.3 Hz, 1H), 7.03-7.01 (m, 2H), 6.67-6.58 (m, 4H), 4.39-4.34 (m, 6H),
11
12 3.78 (3H, s), 3.37 (t, *J* = 7.1 Hz, 2H), 2.86 (t, *J* = 5.6 Hz, 2H), 2.23 (s, 6H), 2.18 (s, 6H), 1.91 (m,
13
14 2H), 1.82 (m, 2H); ¹³C NMR (125 MHz, DMSO-d₆): δ 158.2, 149.9, 143.3, 142.4, 139.6, 139.5,
15
16 133.6, 130.9, 127.6, 125.7, 124.3, 122.6, 122.2, 119.2, 117.6, 115.4, 114.9, 114.3, 113.4, 109.5,
17
18 109.1, 66.1, 55.7, 55.3, 55.1, 45.4, 44.6, 44.3, 26.3, 26.0; HRMS (ESI) Calcd for C₃₆H₄₅N₄O₂
19
20 [M+H]⁺ 565.35358, Found 565.3535.

21
22
23
24
25
26
27
28 **N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)thiazol-2-**
29 **amine (Amine 4f).** Following the GP, the reaction of aldehyde **1** with amine **2f** (32 mg)
30
31 afforded **4f** (58 mg, 65 %) as a brown viscous liquid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.38 (s,
32
33 1H), 8.21 (s, 1H), 8.16 (m, 1H), 7.71 (m, 3H), 7.69 (m, 1H), 7.67 (m, 1H), 7.63 (m, 2H), 7.03
34
35 (m, 2H), 4.65 (s, 2H), 4.42 (t, *J* = 6.3 Hz, 2H), 3.81 (s, 3H), 2.30 (t, *J* = 6.9 Hz, 2H), 2.19 (s, 6H),
36
37 1.94 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆): δ 169.1, 158.2, 139.7, 139.4, 138.6, 133.6, 133.1,
38
39 130.9, 129.6, 127.6, 125.3, 124.2, 122.7, 121.9, 118.7, 117.6, 114.3, 109.5, 106.1, 63.5, 55.7,
40
41 55.1, 45.5, 44.5, 25.9; HRMS (ESI) Calcd for C₃₆H₄₅N₄O₂ [M+H]⁺ 471.2140, Found 471.2141.

42
43
44
45
46
47
48
49 **N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)butan-1-**
50 **amine (Amine 4g).** Following the GP, the reaction of aldehyde **1** with amine **2g** (9.5 mg)
51
52 afforded **4g** (46 mg, 69%) as a brown viscous liquid. ¹H NMR (500 MHz, DMSO-d₆): δ 8.35 (s,
53
54
55
56
57
58
59
60

1
2
3 1H), 8.22 (s, 1H), 7.69 (d, $J = 7.4$ Hz, 3H), 7.61 (d, $J = 8.3$ Hz, 1H), 7.55 (d, $J = 8.4$ Hz, 1H),
4
5 7.49 (d, $J = 8.5$ Hz, 1H), 7.04 (d, $J = 8.3$ Hz, 2H), 4.40 (t, $J = 6.1$ Hz, 2H), 3.96 (3H, s), 3.80 (s,
6
7 2H), 2.64 (t, $J = 7.1$ Hz, 2H), 2.18 (t, $J = 6.5$ Hz, 2H), 2.12 (s, 6H), 1.90 (m, 2H), 1.50 (m, 2H),
8
9 1.32 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 2H), 0.86 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (125 MHz, DMSO- d_6):
10
11 δ 158.2, 139.9, 139.5, 133.6, 130.9, 127.7, 126.7, 124.4, 122.6, 122.1, 120.6, 117.6, 114.3, 109.6,
12
13 109.0, 56.0, 55.1, 52.7, 52.0, 47.7, 45.1, 30.5, 26.5, 19.8, 13.9; HRMS (ESI) Calcd for
14
15 $\text{C}_{29}\text{H}_{38}\text{N}_3\text{O}$ $[\text{M}+\text{H}]^+$ 444.3005, Found 444.3008.
16
17
18
19
20
21

22 **N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)prop-2-yn-**

23
24 **1-amine (Amine 4h).** Following the GP, the reaction of aldehyde **1** with amine **2h** (7.2 mg)
25
26 afforded **4h** (33 mg, 59 %) as a yellow liquid. ^1H NMR (500 MHz, CDCl_3): δ 8.25 (s, 1H), 8.11
27
28 (s, 1H), 7.65 (m, 3H), 7.45 (m, 3H), 7.02 (d, $J = 8.5$ Hz, 2H), 4.39 (t, $J = 6.8$ Hz, 2H), 4.08 (s,
29
30 2H), 3.88 (s, 3H), 3.50 (d, $J = 2.0$ Hz, 1H), 2.31 (t, $J = 7.1$ Hz, 2H), 2.24 (s, 6H), 2.04 (m, 2H),
31
32 1.80 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 158.6, 140.4, 140.0, 134.8, 132.0, 129.9, 128.2,
33
34 126.6, 124.9, 123.2, 123.1, 120.3, 118.4, 114.2, 109.0, 108.8, 82.3, 71.5, 56.6, 55.4, 52.7, 45.4,
35
36 40.9, 37.3, 29.7, 27.0; HRMS (ESI) Calcd for $\text{C}_{28}\text{H}_{32}\text{N}_3\text{O}$ $[\text{M}+\text{H}]^+$ 426.2545, Found 426.2542.
37
38
39
40
41

42 **N1-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)-N3,N3-**

43
44 **dimethylpropane-1,3-diamine (Amine 4i).** Following the GP, the reaction of aldehyde **1** with
45
46 amine **2i** (25 mg) afforded **4i** (48 mg, 79 %) as a brown viscous liquid. ^1H NMR (400 MHz,
47
48 CDCl_3): δ 8.15 (s, 1H), 7.91 (s, 1H), 7.54 (m, 2H), 7.35 (m, 2H), 7.17 (m, 2H), 7.10 (m, 2H),
49
50 4.30 (t, $J = 6.1$ Hz, 2H), 3.79 (s, 3H), 3.73 (s, 2H), 2.55 (t, $J = 6.0$ Hz, 2H), 2.36 (t, $J = 7.1$ Hz,
51
52 2H), 2.21 (t, $J = 6.1$ Hz, 2H) 2.20 (t, $J = 5.9$ Hz, 2H), 2.14 (s, 12H), 1.95 (m, 2H); ^{13}C NMR (100
53
54
55
56
57
58
59
60

1
2
3 MHz, CDCl₃): δ 158.3, 148.4, 144.2, 140.6, 135.1, 132.4, 129.7, 129.1, 127.6, 126.7, 125.6,
4
5 124.4, 121.8, 120.5, 111.7, 109.6, 65.1, 57.0, 56.2, 55.1, 46.3, 45.5, 41.0, 29.8, 26.9; HRMS
6
7 (ESI) Calcd for C₃₆H₄₅N₄O₂ [M+H]⁺ 473.3235, Found 473.3233.
8
9

10
11
12 **N-((9-(3-(dimethylamino)propyl)-6-(4-methoxyphenyl)-9H-carbazol-3-yl)methyl)cyclopropanamine**
13
14 **(Amine 4j)**. Following the **GP**, the reaction of aldehyde **1** with amine **2j** (25.8 mg) afforded **4j**
15
16 (50 mg, 69 %) as a yellow viscous liquid. ¹H NMR (400 MHz, CDCl₃): δ 8.25 (s, 1H), 8.08 (s,
17
18 1H), 7.64 (m, 2H), 7.43 (m, 4H), 7.01 (m, 2H), 4.38 (t, *J* = 6.0 Hz, 2H), 4.04 (s, 2H), 3.87 (s,
19
20 3H), 2.32 (t, *J* = 6.0 Hz, 2H), 2.24 (s, 6H), 2.23 (m, 1H), 2.04 (m, 2H), 0.43 (m, 4H); ¹³C NMR
21
22 (100 MHz, CDCl₃): δ 158.8, 140.4, 140.2, 134.9, 132.2, 130.8, 128.4, 126.8, 125.1, 123.5, 123.2,
23
24 120.3, 118.5, 114.4, 109.1, 108.9, 56.8, 55.5, 54.2, 46.1, 45.5, 30.2, 27.0, 9.3; HRMS (ESI)
25
26 Calcd for C₃₆H₄₅N₄O₂ [M+H]⁺ 428.2657, Found 428.2653.
27
28
29
30
31
32

33 **FRET-based DNA melting assay.** FRET melting assay was carried out on a real-time PCR
34
35 apparatus (Roche LightCycler 480 II) using dual labelled DNA sequences. The DNA sequences
36
37 labelled with 6-FAM (donor fluorophore) at 5'-end and TAMRA (acceptor fluorophore) at 3'-
38
39 end were purchased from Eurofins Genomics. The fluorescently labelled oligonucleotides (G₄-
40
41 DNA and dsDNA) were annealed in 60 mM potassium cacodylate buffer (pH 7.4) at a
42
43 concentration of 400 nM by heating at 95 °C for 5 min followed by gradual cooling to room
44
45 temperature at a controlled rate of 0.1 °C/min. Fluorescence melting curves were recorded using
46
47 a total reaction volume of 100 μL, with 200 nM labelled oligonucleotide in Tris-KCl buffer (pH
48
49 7.4) in the absence and/or presence of 1 μM of each amine product (**4a-4j**). Measurements were
50
51 done with excitation at 480 nm and detection at 530 nm. Fluorescence readings were taken with
52
53
54
55
56
57
58
59
60

1
2
3 a ramp rate of 0.01 °C with 30 acquisitions per °C over the range 37–95 °C. Sequences used in
4
5 the FRET studies are as follows;
6

7 G₄-DNA: 5'-FAM -TG₄AG₃TG₄AG₃TG₄A₂G₂ - TAMRA-3'

8
9
10 dsDNA: 5'- FAM-CA₅T₅GCA₅T₅G - TAMRA-3'

11
12
13
14 **Fluorimetric titration.** Fluorescence emission spectra were recorded on incremental addition of
15 DNA into the 0.25 μM ligand solution. The fluorescence spectra were recorded on a Horiba
16 Jobin Yvon Fluoromax 3 instrument at 25 °C in a thermo-stated cell holder using quartz cuvette
17 with a 1 cm path-length. The spectra were taken using filtered and degassed buffer (100 mM
18 Tris.KCl, pH 7.4) solution. DNA sequences used in the biophysical experiments:
19
20
21
22
23
24

25
26 G₄-DNA: 5'-TG₄AG₃TG₄AG₃TG₄A₂G₂ -3'

27
28 dsDNA: 5'- CA₅T₅GCA₅T₅G -3'

29
30
31
32
33 The binding constants were calculated using the following Hill 1 equation (1) with Origin Pro
34
35 8.0:

$$36$$
$$37$$
$$38 F = F_0 + \frac{(F_{max} - F_0)[DNA]}{K_d + [DNA]} \text{ (Equation 1)}$$
$$39$$

40
41 where F is the fluorescence intensity, F_{max} is the maximum fluorescence intensity, F₀ is the
42 fluorescence intensity in the absence of DNA and K_d is the apparent dissociation constant.
43
44
45
46
47

48 **Fluorescent intercalator displacement (FID) assay.** Pre-folded DNA target (0.25 μM) was
49 mixed with thiazole orange (0.50 μM) in Tris–KCl buffer (100 mM, pH 7.4) in a total volume of
50 0.5 mL and incubated for 30 min at rt. Fluorescence spectrum was recorded after addition of
51 each compound followed by a 3 min equilibration period. The percentage of TO displacement
52
53
54
55
56
57
58
59
60

1
2
3 was calculated from the fluorescence area (F_A , 510–750 nm; excitation, 501 nm) of the spectra
4
5 using following equation;

$$\% \text{ of TO displacement} = 100 - [FA \times 100 / FA_0]$$

6
7
8
9
10 FA_0 is the fluorescence area from TO bound to the DNA in absence of any ligand. The DC_{50}
11
12 values were calculated from the plot of percentage of TO displacement vs the concentration of
13
14 the ligands.
15

16
17 **Cell Culture Conditions.** Human cervical cancer cell line HeLa, human small lung carcinoma
18
19 cell line A549, and human normal kidney epithelial cell line NKE were maintained at 37 °C with
20
21 5% CO₂. HeLa cells were grown in DMEM (Himedia) and A549 cells are grown in Ham's F12K
22
23 (Himedia). Normal human cell line was maintained in Glutamine supplemented RPMI 1640
24
25 (GIBCO) media. The media were supplemented with 10% FBS (GIBCO) and 1% anti-anti
26
27 (GIBCO).
28
29

30
31
32
33 **XTT cell viability assay.** XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
34
35 [(phenylamino)carbonyl]-2*H*-tetrazolium hydroxide) assay was performed to determine the
36
37 cytotoxicity of the compounds in cells. Viability experiments were performed in triplicate on 96-
38
39 well plates at designated doses. Cells were grown at a density of 10⁴-10⁵ cells/well in 100 μL of
40
41 culture medium and treated with increasing concentrations of the compounds (0-50 μM) and
42
43 incubated for 24 h. The XTT/PMS reagent was prepared by mixing 1 mg of XTT in 1 mL of
44
45 culture medium followed by the addition of 2.5 μL of 10 mM PMS solution (in PBS). 25 μL of
46
47 this freshly prepared reagent mixture was then directly added to each well containing 100 μL of
48
49 culture media and incubated for 2 h at 37 °C. The absorbance of XTT formazan was read at 450
50
51
52
53
54
55
56
57
58
59
60

1
2
3 nm on Multiskan FC microplate spectrophotometer (Thermo Scientific). Percentage cell viability
4
5 was calculated by using the following equation:
6

$$7 \quad \% \text{ of cell viability} = \frac{\text{O.D. of treated cells}}{\text{O.D. of untreated control cells}} \times 100$$

8
9
10
11
12

13 **Dual luciferase reporter assay.** 0.2 μg of Del4 plasmid construct (Addgene plasmid #16604-
14 Del4) containing the minimal promoter region of *c-MYC* G-quadruplex sequence was transfected
15 into HeLa cells using Lipofectamine 2000 (Invitrogen). 30 ng of Renilla luciferase plasmid
16 construct (pRL-TK) was co-transfected as a transfection control for normalization. Transfection
17 was performed in serum-free DMEM medium and after 8 h media was replaced with complete
18 media and treated with ligands at respective concentrations. After 36 h, cells were harvested,
19 lysed with 1x passive lysis buffer and luciferase activities of cell lysate were measured using a
20 Dual-Luciferase reporter assay kit (Promega). The assay was also performed with mutant *c-MYC*
21 Del4 plasmid construct (0.2 μg) containing a G-to-A point mutation in the *c-MYC* G-rich region.
22
23
24
25
26
27
28
29
30
31
32

33
34
35 **Western Blot.** Cells were collected after 24 h post-treatment of ligand **4e**, washed with ice cold
36 PBS twice, and lysed with cold cell lysis buffer (20 mM Tris, 100 mM NaCl, 1 mM EDTA in
37 0.5% Triton X-100) for 30 min on ice, and debris was removed by centrifugation at 12000g for
38 15 min. Aliquots of the supernatants were used for protein determination by Folin-Lowry
39 method. Equal amounts of protein (70 μg) were subjected to 12 % SDS PAGE, and after gel
40 electrophoresis, the proteins were electrophoretically transferred onto nitrocellulose membranes.
41 Then, membranes were blocked with 4 % BSA for 2 h and then incubated overnight at 4 $^{\circ}\text{C}$ with
42 different primary antibodies. The membranes were washed three times with 1x TBST and then
43 incubated for 2 h with HRP linked respective secondary antibodies. Blots were washed thrice
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with 1x TBST and then once with 1x TBS and bands were acquired by the addition of TMB or
4
5 NBD/BCIP substrate. Relative band intensities were determined by using ImageJ software.
6

7
8 Primary antibodies used:

9
10 Anti c-MYC antibody - Rabbit origin (Invitrogen)

11
12 Anti GAPDH antibody - Mouse origin (Invitrogen)
13
14
15
16

17 **Confocal Microscopy of ligand treated cells.** The cells were grown on coverslips in six-well
18
19 plates and treated with 0.5 μM **4e** for overnight. After the incubation, the cells were washed with
20
21 ice-cold PBS and fixed for 12 min with 1:1 acetone/methanol at -20 °C. The cells were then
22
23 washed thrice in ice-cold PBS, stained with NucRed 647 Live and kept at room temperature in
24
25 the dark for 10 min. Images were taken in Olympus confocal laser scanning microscope (model
26
27 IX81, v 4.1). The raw data was analyzed in Fluoview FV10-ASW v 4.2 software.
28
29
30
31
32

33 **Flow cytometry with Alexa fluor 647-tagged anti- γH2AX .** Cells were grown in six-well plates
34
35 and treated with 1 and 2 μM **4e** for overnight. After incubation with the ligand, cells were
36
37 washed with 1X PBS and collected by trypsinization. The cell pellet was then washed with 1X
38
39 PBS containing 0.1% FBS. Cells were then fixed with 1 % paraformaldehyde (500 μL) for 30
40
41 min at room temperature and then perforated by 0.03 % saponin (freshly prepared in MilliQ
42
43 water). After 20 min incubation in room temperature with saponin, cells were washed with 1X
44
45 PBS containing 0.1% FBS. Then the cells were incubated with Alexa fluor 647-tagged anti-
46
47 γH2AX (50 μL , 1:100 dilution in 1X PBS+0.1% FBS) for 3 h. Next, 300 μL 1X PBS+0.1% FBS
48
49 mixture was added and cells were then analysed by flow cytometry (BD FACS Aria III).
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Binding mode of amine 4e and imine 3e with G₄-DNA.** The energy minimized structures of
4 amine 4e and imine 3e were obtained with Gaussian 03 using density functional theory (DFT)
5 analysis B3LYP/6-31+G(d) level. Docking studies were performed with the lowest energy
6 conformer of ligands and G₄-DNA (PDB ID: 1XAV)⁵⁹ using the Auto-Dock 4.0 program. 30
7 docking calculations were performed using the Lamarckian genetic algorithm (LGA) with Auto-
8 Dock 4.0 program. The ligand structures were energy minimized using Gaussian 09 (B3LYP/6-
9 31G* level). The coordinates of *c-MYC* (PDB entry: 1XAV) G-quadruplex DNA structure was
10 retrieved and prepared for docking. The grid box was centered on the *c-MYC* G-quadruplex
11 DNA with a grid size enough to encompass the full receptor molecule. Hence, all possible
12 binding modes, intercalation, end stacking, and groove-binding, could be revealed by docking
13 studies. A maximum of 25 million energy evaluations were applied for the experiment. The
14 conformation corresponding to the most cluster members and the lowest binding free energy was
15 selected as the most probable binding conformation. The docked complex structures were
16 imaged using Chimera 1.11.2 software.

37 ASSOCIATED CONTENT

38
39
40
41 **Supporting Information.** The Supporting Information is available free of charge on the ACS
42 Publications website at DOI: 10.1021/acs.jmedchem.XX.

43
44
45
46 Additional experimental results, ¹H and ¹³C NMR spectra and HPLC chromatograms of
47 the final compounds, reaction schemes, normalized fluorescence responses of ligands, FID
48 curves.
49
50
51

52
53
54 Molecular formula strings
55
56
57
58
59
60

AUTHOR INFORMATION

Corresponding Author

*Phone: +91 33 2473 4971, Ext 1405. Email: ocjd@iacs.res.in

Author Contributions

†These authors contributed equally.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

JD thanks DST for a SwarnaJayanti fellowship. The authors thank DBT, DST and CSIR-India for research funding. SJ thanks CSIR-INDIA and DP thanks DST, India for research fellowships. The authors thank Mr. Arijit Pal for confocal microscopy, DBT-IPLS unit, University of Calcutta.

REFERENCES

- (1) Lehn, J. M. Dynamic combinatorial chemistry and virtual combinatorial libraries. *Chem.-Eur. J.* **1999**, *5*, 2455-2463.
- (2) Otto, S.; Furlan, R. L.; Sanders, J. K. M. Recent developments in dynamic combinatorial chemistry. *Curr. Opin. Chem. Biol.* **2002**, *6*, 321-327.

- 1
2
3 (3) Otto, S.; Furlan, R. L. E.; Sanders, J. K. M. Dynamic combinatorial chemistry. *Drug Discov.*
4 *Today* **2002**, *7*, 117-125.
5
6
7
8 (4) Mamidyala, S. K.; Finn, M. G. *In Situ* click chemistry: Probing the binding landscapes of
9 biological molecules. *Chem. Soc. Rev.* **2010**, *39*, 1252-1261.
10
11
12
13 (5) Corbett, P. T.; Leclaire, J.; Vial, L.; West, K. R.; Wietor, J. L.; Sanders, J. K. M.; Otto S.
14 Dynamic combinatorial chemistry. *Chem. Rev.* **2006**, *106*, 3652-3711.
15
16
17
18 (6) Hu, X.; Manetsch, R. Kinetic target-guided synthesis. *Chem. Soc. Rev.* **2010**, *39*, 1316-1324.
19
20
21
22 (7) Cougnon, F. B. L.; Sanders, J. K. M. Evolution of dynamic combinatorial chemistry. *Acc.*
23 *Chem. Res.* **2011**, *45*, 2211-2221.
24
25
26
27 (8) Corbett, P. T.; Tong, L. H.; Sanders, J. K. M.; Otto, S. Diastereoselective amplification of an
28 induced-fit receptor from a dynamic combinatorial library. *J. Am. Chem. Soc.* **2005**, *127*, 8902-
29 8903.
30
31
32
33 (9) Ramström, O.; Lehn, J. M. Drug discovery by dynamic combinatorial libraries. *Nat. Rev.*
34 *Drug Discov.* **2002**, *1*, 26-36.
35
36
37
38 (10) Hamieh, S.; Ludlow, R. F.; Perraud, O.; West, K. R.; Mattia, E.; Otto S. A synthetic
39 receptor for nicotine from a dynamic combinatorial library. *Org. Lett.* **2012**, *14*, 5404-5407.
40
41
42
43 (11) Leung, K. C. F.; Arico, F.; Cantrill, S. J.; Stoddart, J. F. Dynamic mechanically interlocked
44 dendrimers: amplification in dendritic dynamic combinatorial libraries. *Macromolecules* **2007**,
45 *40*, 3951-3959.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (12) Ziach, K.; Obrocka-Hrycyna, A.; Jurczak, J. Dynamic combinatorial libraries of 2,5-
4 diformylfuran-derived macrocycles. *J. Org. Chem.* **2014**, *79*, 10334-10341.
5
6
7
8 (13) Gasparini, G.; Molin, M. D.; Prins, L. J. Dynamic approaches towards catalyst discovery.
9 *Eur. J. Org. Chem.* **2010**, 2429–2440.
10
11
12
13 (14) Li, J.; Nowak, P.; Otto, S. Dynamic combinatorial libraries: from exploring molecular
14 recognition to systems chemistry. *J. Am. Chem. Soc.* **2013**, *135*, 9222-9239.
15
16
17
18 (15) Huc, I.; Lehn, J. M. Virtual combinatorial libraries: dynamic generation of molecular and
19 supramolecular diversity by self-assembly. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 2106-2110.
20
21
22
23 (16) Bunyapaiboonsri, T.; Ramström, O.; Lohmann, S.; Lehn, J. M.; Peng, L.; Goeldner, M.
24 Dynamic deconvolution of a pre-equilibrated dynamic combinatorial library of
25 acetylcholinesterase inhibitors. *ChemBioChem* **2001**, *2*, 438-444.
26
27
28
29 (17) Shi, B.; Stevenson, R.; Campopiano, D. J.; Greaney, M. F. Discovery of Glutathione S-
30 Transferase inhibitors using dynamic combinatorial chemistry. *J. Am. Chem. Soc.* **2006**, *128*,
31 8459-8467.
32
33
34
35 (18) Milanesi, L.; Hunter, C. A.; Sedelinkova, S. E.; Waltho, J. P. Amplification of bifunctional
36 ligands for calmodulin from a dynamic combinatorial library. *Chem.–Eur. J.*, **2006**, *12*, 1081-
37 1087.
38
39
40 (19) Klekota, B.; Hammond, M. H.; Miller, B. L. Generation of novel DNA-binding compounds
41 by selection and amplification from self-assembled combinatorial libraries. *Tetrahedron Lett.*
42 **1997**, *38*, 8639-8642.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (20) Bugaut, A.; Toulmé, J. J.; Rayner, Use of dynamic combinatorial chemistry for the
4 identification of covalently appendend residue that stabilize oligonucleotide complexes. *Angew.*
5
6
7
8 *Chem. Int. Ed.* **2004**, *43*, 3144-3147.

9
10
11 (21) Bugaut, A.; Bathany, K.; Schmitter, J. M.; Rayner, B. Target-induced selection of ligands
12 from a dynamic combinatorial library of mono- and bi-conjugated oligonucleotides. *Tetrahedron*
13
14
15 *Lett.* **2005**, *46*, 687-690.

16
17
18 (22) Whitney, A. M.; Ladame, S.; Balasubramanian, S. Templated ligand assembly by using g-
19 quadruplex DNA and dynamic covalent chemistry. *Angew. Chem. Int. Ed.* **2004**, *43*, 1143-1146.

20
21
22 (23) Ladame, S.; Whitney, A. M.; Balasubramanian, S. Targeting nucleic acid secondary
23 structures with polyamides using an optimized dynamic combinatorial approach. *Angew. Chem.*
24
25
26
27
28 *Int. Ed.* **2005**, *44*, 5736-5739.

29
30
31 (24) Bugaut, A.; Jantos, K.; Wietor, J. L.; Rodriguez, R.; Sanders, J. K.; Balasubramanian, S.
32 Exploring the differential recognition of DNA G-quadruplex targets by small molecules using
33 dynamic combinatorial chemistry. *Angew. Chem. Int. Ed.* **2008**, *47*, 2677-2680.

34
35
36 (25) Karan, C.; Mille, B. L. RNA-selective coordination complexes identified via dynamic
37 combinatorial chemistry. *J. Am. Chem. Soc.* **2001**, *123*, 7455-7456.

38
39
40 (26) Gareiss, P. C; Sobczak, K.; McNaughton, B. R.; Palde, P. B.; Thornton, C. A.; Miller, B. L.
41 Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat
42 RNA–MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy
43
44
45
46
47
48
49
50
51
52 (DM1). *J. Am. Chem. Soc.* **2008**, *130*, 16254-16261.

- 1
2
3 (27) Ofori, L. O.; Hoskins, J.; Nakamori, M.; Thornton, C. A.; Miller, B. L. From dynamic
4 combinatorial 'hit' to lead: *in vitro* and *in vivo* activity of compounds targeting the pathogenic
5 RNAs that cause myotonic dystrophy. *Nucleic Acids Res.* **2012**, *40*, 6380-6390.
6
7
8
9
10
11 (28) McNaughton, B. R.; Miller, B. L. Resin-bound dynamic combinatorial chemistry. *Org. Lett.*
12
13 **2006**, *8*, 1803-1806.
14
15
16 (29) Nowak, P.; Saggiomo, V.; Salehian, F.; Colomb-Delsuc, M.; Han, Y.; Otto, S. Localized
17 template-driven functionalization of nanoparticles by dynamic combinatorial chemistry. *Angew.*
18 *Chem. Int. Ed.* **2015**, *54*, 4192-4197.
19
20
21
22
23
24 (30) Han, Y.; Nowak, P.; Colomb-Delsuc, M.; Leal, M. P.; Otto, S. Instructable nanoparticles
25 using dynamic combinatorial chemistry. *Langmuir* **2015**, *31*, 12658-12663.
26
27
28
29
30 (31) Otto, S.; Furlan, R. L. E.; Sanders, J. K. M. Dynamic combinatorial libraries of macrocyclic
31 disulfides in water. *J. Am. Chem. Soc.* **2000**, *122*, 12063-12064.
32
33
34
35 (32) Chakravarthi, S.; Jessop, C. E.; Bulleid, N. J. The role of glutathione in disulphide bond
36 formation and endoplasmic-reticulum-generated oxidative stress. *EMBO Rep.* **2006**, *7*, 271-275.
37
38
39
40 (33) Panda, D.; Saha, P.; Das, T.; Dash, J. Target guided synthesis using dna nano-templates for
41 selectively assembling a G-quadruplex binding *c-MYC* inhibitor. *Nat. Commun.* **2017**, *8*, 16103.
42
43
44
45 (34) Huppert, J. L.; Balasubramanian, S. Prevalence of quadruplexes in the human genome.
46 *Nucleic Acids Res.* **2005**, *33*, 2908-2916.
47
48
49
50
51 (35) Murat, P.; Balasubramanian, S. Existence and consequences of G-quadruplex structures in
52 DNA. *Curr. Opin. Genet. Dev.* **2014**, *25*, 22-29.
53
54
55
56
57
58
59
60

1
2
3 (36) Chambers, V. S.; Marsico, G.; Boutell, J. M.; Antonio, M. Di; Smith, G. P.;
4 Balasubramanian, S. High-throughput sequencing of DNA G-quadruplex structures in the human
5 genome. *Nat. Biotechnol.* **2015**, *33*, 877-881.
6
7

8
9
10 (37) Neidle, S. Quadruplex nucleic acids as novel therapeutic targets. *J. Med. Chem.* **2016**, *59*,
11 5987-6011.
12
13

14
15 (38) Hansel-Hertsch, R.; Antonio, M. Di; Balasubramanian, S. DNA G-quadruplexes in the
16 human genome: detection, functions and therapeutic potential. *Nat. Rev. Mol. Cell. Bio.* **2017**,
17 *18*, 279-284.
18
19

20
21 (39) Neidle, S. Quadruplex nucleic acids as targets for anticancer therapeutics. *Nat. Rev. Chem.*
22 **2017**, *1*, 0041.
23
24

25
26 (40) Brockmann, A.; Strittmatter, T.; May, S.; Stemmer, K.; Marx, A.; Brunner, T. Structure–
27 function relationship of thiazolide-induced apoptosis in colorectal tumor cells. *ACS Chem. Biol.*
28 **2010**, *9*, 1520-1527.
29
30

31
32 (41) Monchaud, D.; Teulade-Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. *Org.*
33 *Biomol. Chem.* **2008**, *6*, 627-636.
34
35

36
37 (42) Tian, T.; Chen, Y. Q.; Wang, S. R.; Zhou, X. G-quadruplex: A regulator of gene expression
38 and its chemical targeting. *Chem* **2018**, *4*, 1314-1344.
39
40

41
42 (43) Tera, M.; Ishizuka, H.; Takagi, M.; Suganuma, M.; Shin-ya, K.; Nagasawa, K. Macrocyclic
43 hexaoxazoles as sequence- and mode-selective G-quadruplex binders. *Angew. Chem. Int. Ed.*,
44 **2008**, *47*, 5557–5560.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 (44) Maji, B.; Kumar, K.; Kaulage, M.; Muniyappa, K.; Bhattacharya, S. Design and synthesis of
4 new benzimidazole–carbazole conjugates for the stabilization of human telomeric DNA,
5 telomerase inhibition, and their selective action on cancer cells. *J. Med. Chem.* **2014**, *57*, 6973-
6 6988.
7
8
9
10
11
12
13 (45) Zhang, X.; Chi, L.; Ji, S.; Wu, Y.; Song, P.; Han, K.; Guo, H.; James, T. D.; Zhao, J.
14 Rational design of d-PeT phenylethynylated-carbazole monoboronic acid fluorescent sensors for
15 the selective detection of α -hydroxyl carboxylic acids and monosaccharides. *J. Am. Chem. Soc.*
16 **2009**, *131*, 17452-17463.
17
18
19
20
21
22
23 (46) Zhao, L.; Wagner, P.; Elliott, A. B. S.; Griffith, M. J.; Clarke, T. M.; Gordon, K. C.; Mori,
24 S.; Mozer, A. J. Enhanced performance of dye-sensitized solar cells using carbazole-substituted
25 di-chromophoric porphyrin dyes. *J. Mater. Chem. A* **2014**, *2*, 16963-16977.
26
27
28
29
30
31 (47) Wang, C.; Jia, G.; Zhou, J.; Li, Y.; Liu, Y.; Lu, S.; Li, C. Enantioselective Diels–Alder
32 reactions with G-quadruplex DNA-based catalysts. *Angew. Chem. Int. Ed.* **2012**, *51*, 9352-9355.
33
34
35
36
37 (48) Siddiqui-Jain, A.; Grand, C. L.; Bearss, D. J.; Hurley, L. H. Direct evidence for a G-
38 quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC
39 transcription. *P. Natl. Acad. Sci. USA* **2002**, *99*, 11593-11598.
40
41
42
43
44 (49) Mathad, R. I.; Hatzakis, E.; Dai, J. X.; Yang, D. Z. c-MYC promoter G-quadruplex formed
45 at the 5'-end of NHE III₁ element: insights into biological relevance and parallel-stranded G-
46 quadruplex stability. *Nucleic Acids Res.* **2011**, *39*, 9023-9033.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (50) De Cian, A.; Guittat, L.; Kaiser, M.; Sacca, B.; Amrane, S.; Bourdoncle, A.; Alberti, P.;
4 Teulade-Fichou, M. P.; Lacroix, L.; Mergny, J. L. Fluorescence-based melting assays for
5
6 studying quadruplex ligands. *Methods* 2007, **42**, 183-195.
7

8
9
10 (51) Monchaud, D; Allain, C.; Bertrand, H.; Smargiasso, N.; Rosu, F.; Gabelica, V.; De Cian, A.;
11
12 Mergny, J. L.; Teulade-Fichou, M. R. Ligands playing musical chairs with G-quadruplex DNA:
13
14 a rapid and simple displacement assay for identifying selective g-Guadruplex binders. *Biochimie*
15
16 **2008**, *90*, 1207-1223.
17

18
19
20 (52) Halder, K.; Benzler, M.; Hartig, J. S. Reporter Assays for studying quadruplex nucleic
21
22 acids. *Methods* **2012**, *57*, 115-121.
23

24
25
26 (53) He, T. C.; Sparks, A. B.; Rago, C.; Hermeking, H.; Zawel, L.; da Costa, L. T.; Morin, P. J.;
27
28 Vogelstein, B.; Kinzler, K. W. Identification of c-MYC as a target of the APC pathway. *Science*
29
30 **1998**, *281*, 1509-1512.
31

32
33
34 (54) Kumar, Y. P.; Saha, P.; Saha, D.; Bessi, I.; Schwalbe, H.; Chowdhury, S.; Dash, J.
35
36 Fluorescent dansyl-guanosine conjugates that bind *c-MYC* promoter G-quadruplex and
37
38 downregulate *c-MYC* Expression. *ChemBioChem* **2016**, *17*, 388-393.
39

40
41
42 (55) Chauhan, A.; Paul, R.; Debnath, M.; Bessi, I.; Mandal, S.; Schwalbe, H.; Dash, J. Synthesis
43
44 of fluorescent binaphthyl amines that bind *c-MYC* G-quadruplex DNA and repress *c-MYC*
45
46 expression. *J. Med. Chem.* **2016**, *59*, 7275-7281.
47

48
49
50 (56) Felsenstein, K. M.; Saunders, L. B.; Simmons, J. K.; Leon, E.; Calabrese, D. R.; Zhang, S.
51
52 L.; Michalowski, A.; Gareiss, P.; Mock, B. A.; Schneekloth, J. S. Small molecule microarrays
53
54

1
2
3 enable the identification of a selective, quadruplex-binding inhibitor of MYC expression. *ACS*
4
5 *Chem. Biol.* **2016**, *11*, 139-148.

6
7
8 (57) Hu, M. H.; Wang, Y. Q.; Yu, Z. Y.; Hu, L. N.; Ou, T. M.; Chen, S. B.; Huang, Z. S.; Tan, J.
9
10 H. Discovery of a new four-leaf clover-like ligand as a potent *c-MYC* transcription inhibitor
11
12 specifically targeting the promoter G-quadruplex. *J. Med. Chem.* **2018**, *61*, 2447-2459.

13
14
15 (58) Dutta, D.; Debnath, M.; Müller, D.; Paul, R.; Das, T.; Bessi, I.; Schwalbe, H.; Dash, J. Cell
16
17 penetrating thiazole peptides inhibit c-MYC expression via site-specific targeting of *c-MYC* G-
18
19 quadruplex. *Nucleic Acids Res.* **2018**, *46*, 5355-5365.

20
21
22 (59) Phan, A.T.; Modi, Y. S.; Patel, D. J. Propeller-type parallel-stranded G-quadruplexes in the
23
24 human c-myc promoter. *J. Am. Chem. Soc.* **2004**, *126*, 8710-8716.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents graphic:

